Drug Combination Details
| General Information of the Combination (ID: C17041) | |||||
|---|---|---|---|---|---|
| Name | Triptolide NP Info | + | 5-fluorouracil Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Colorectal cancer
[ICD-11: 2B91]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Up-regulation | ROS generation | ||||
| In-vitro Model | NCI-H630 | CVCL_1572 | Colorectal cancer | Homo sapiens | ||
| HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
| RKO | CVCL_0504 | Colon carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
PG490 strongly enhanced the cytotoxicity of 5-FU. PG490 also simultaneously induced ROS and inhibited NF-KappaB activity and significantly enhanced the cytotoxic effect of 5-FU in three CRC cell lines in vitro. | |||||
